aztreonam has been researched along with Lymphoma in 6 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourty-two febrile episodes of 32 patients with hematologic disease during neutropenia were treated with two randomly assigned antibiotic combinations of either piperacillin plus gentamicin or piperacillin plus aztreonam." | 9.07 | [Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases]. ( Murase, T, 1992) |
| "Fourty-two febrile episodes of 32 patients with hematologic disease during neutropenia were treated with two randomly assigned antibiotic combinations of either piperacillin plus gentamicin or piperacillin plus aztreonam." | 5.07 | [Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases]. ( Murase, T, 1992) |
| " Thus, both the adverse prognostic effect of leukemia as an underlying disease and the poorer results obtained using aztreonam-containing regimens were evident only with certain outcome definitions." | 5.06 | The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. ( Elliott, CR; Pater, JL, 1988) |
| "Nineteen patients with hematological malignancies (5 malignant lymphomas, 9 acute leukemia and 5 other hematological diseases) were treated with aztreonam alone or in combination for infection." | 3.67 | Treatment of infections during hematologic malignancies with aztreonam, a new antibiotic. ( Invernizzi, R; Mazzone, A; Nastasi, G; Ricevuti, G; Rizzo, SC, 1986) |
| "One hundred and nine patients with infection accompanying hematologic disorders including leukemia and lymphoma were treated with aztreonam (AZT)." | 3.67 | [Therapeutic effectiveness of aztreonam on severe infections associated with hematologic disorders. Hanshin Infection Study Group]. ( Hirayama, F; Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Okamoto, Y; Shibata, H; Yasunaga, K; Yonezawa, T, 1985) |
| "There was one infection-related death among patients assigned to AAT therapy and also one among those assigned to LAT therapy." | 2.66 | [Empiric therapy with aztreonam for febrile neutropenic patients with hematological malignancies]. ( Ichimaru, M; Moriuchi, Y; Soda, H; Tomonaga, M; Toriya, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toyama, K | 1 |
| Yaguchi, M | 1 |
| Mizoguchi, H | 1 |
| Masuda, M | 1 |
| Urabe, A | 1 |
| Ikeda, Y | 1 |
| Aoki, I | 1 |
| Shinbo, T | 1 |
| Togawa, A | 1 |
| Hirashima, K | 1 |
| Miura, Y | 1 |
| Hirose, S | 1 |
| Tsuruoka, N | 1 |
| Omine, M | 1 |
| Kamakura, M | 1 |
| Saito, T | 1 |
| Arimori, S | 1 |
| Aoki, N | 1 |
| Kuraishi, Y | 1 |
| Hirai, H | 1 |
| Asano, S | 1 |
| Mori, M | 1 |
| Shirai, T | 1 |
| Muto, Y | 1 |
| Takaku, F | 1 |
| Murase, T | 1 |
| Moriuchi, Y | 1 |
| Soda, H | 1 |
| Toriya, K | 1 |
| Tomonaga, M | 1 |
| Ichimaru, M | 1 |
| Elliott, CR | 1 |
| Pater, JL | 1 |
| Rizzo, SC | 1 |
| Ricevuti, G | 1 |
| Invernizzi, R | 1 |
| Mazzone, A | 1 |
| Nastasi, G | 1 |
| Hirayama, F | 1 |
| Masaoka, T | 1 |
| Shibata, H | 1 |
| Nagai, K | 1 |
| Kitani, T | 1 |
| Horiuchi, A | 1 |
| Kawagoe, H | 1 |
| Yasunaga, K | 1 |
| Okamoto, Y | 1 |
| Yonezawa, T | 1 |
4 trials available for aztreonam and Lymphoma
| Article | Year |
|---|---|
Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Clindamycin; Drug Therapy, Com | 1996 |
[Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases].
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Aztreonam; Bacterial Infections; Cefamandole; Drug Therap | 1992 |
[Empiric therapy with aztreonam for febrile neutropenic patients with hematological malignancies].
Topics: Aztreonam; Drug Evaluation; Drug Therapy, Combination; Fever; Humans; Infections; Leukemia; Lymphoma | 1989 |
The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients.
Topics: Acute Disease; Agranulocytosis; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Cloxacil | 1988 |
2 other studies available for aztreonam and Lymphoma
| Article | Year |
|---|---|
Treatment of infections during hematologic malignancies with aztreonam, a new antibiotic.
Topics: Acute Disease; Aztreonam; Bacterial Infections; Humans; Leukemia; Lymphoma | 1986 |
[Therapeutic effectiveness of aztreonam on severe infections associated with hematologic disorders. Hanshin Infection Study Group].
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Drug Evaluation; Drug Resistance, Microbia | 1985 |